Viking Therapeutics Prices Upsized $500 Million Stock, Convertible Notes Offering

08:05 AM EDT, 09/24/2026 (MT Newswires) -- Viking Therapeutics (VKTX) has priced concurrent public offerings of about 7.86 million common shares at $35 per share and $225 million of 2.00% convertible senior notes due 2032, the company said Thursday. Underwriters have 30-day options to purchase up to an additional 1.18 million shares and $33.75 million of notes, Viking Therapeutics said. The offerings are expected to close on Friday, the company said. Combined proceeds will be used to continue development of its VK2735 and VK3019 programs, working capital, and general corporate purposes, Viking Therapeutics said.